Milestone Asset Management LLC Purchases 1,037 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Milestone Asset Management LLC lifted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 56.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,874 shares of the biotechnology company's stock after acquiring an additional 1,037 shares during the quarter. Milestone Asset Management LLC's holdings in United Therapeutics were worth $1,014,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in shares of United Therapeutics by 35.4% during the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company's stock valued at $68,999,000 after purchasing an additional 50,291 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock valued at $89,532,000 after acquiring an additional 123,929 shares in the last quarter. Burney Co. increased its stake in shares of United Therapeutics by 113.3% during the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock valued at $8,441,000 after acquiring an additional 12,705 shares during the period. Bridgewater Associates LP raised its holdings in United Therapeutics by 384.3% during the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company's stock worth $22,130,000 after purchasing an additional 49,003 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its position in United Therapeutics by 6.4% in the third quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company's stock worth $24,585,000 after purchasing an additional 4,145 shares during the period. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 5.4 %

UTHR stock traded down $20.26 during midday trading on Thursday, reaching $352.49. 269,949 shares of the company's stock traded hands, compared to its average volume of 278,004. The company has a 50-day simple moving average of $365.77 and a two-hundred day simple moving average of $356.81. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The company has a market cap of $15.74 billion, a price-to-earnings ratio of 15.50, a PEG ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company's revenue was up 22.9% on a year-over-year basis. During the same period last year, the company earned $5.38 earnings per share. Equities research analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent research reports. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. The Goldman Sachs Group boosted their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Finally, UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $378.36.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $955,319.67. This represents a 79.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the transaction, the director now owns 5,655 shares of the company's stock, valued at $2,332,574.40. The trade was a 23.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 149,048 shares of company stock valued at $56,142,199. Company insiders own 11.90% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.